title: Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma.
abstract: Preliminary research results with antibody of the negative costimulatory molecule programmed cell death ligand-1 (PD-L1) suggested its expression on tumor cells associated with various tumor grade and postoperative prognosis. However, to date, there is no information of PD-L1 expression in colorectal serrated adenocarcinoma (SAC) and its clinical relevance. Therefore, the purpose of this study is to investigate the clinical significance of PD-L1 expression in a large cohort of patients with SAC. Here, we first retrospectively identified all SAC collected at our institution between August 2008 and May 2013. The expression levels of PD-L1 were examined by immunohistochemistry in 120 patients with SAC. We further evaluated the correlation between expression data and clinical parameters, including patient age, sex, tumor size, location, grade, primary tumor classification (pT), lymph node metastasis (pN), distant metastases (pM), and vascular invasion. Strong PD-L1 expression was detected in 25% of SAC. Higher expression of PD-L1 was significantly associated with pN (P=0.003) and pM (P=0.014). Survival analysis showed that patients with higher expression of PD-L1 had a poorer prognosis (P=0.045). However, multivariate regression analysis did not support PD-L1 as an independent prognostic factor (P=0.430). Our data suggest that PD-L1 may represent a new biomarker of metastasis and prognosis for patients with SAC, but as a target in the treatment of SAC is less certain.
authors.affiliation: Department of Pathology, Tongji Hospital, Tongji University School of Medicine Shanghai, China.
authors.forename: Hailong
authors.initials: H
authors.lastname: Zhu
authors.affiliation: Department of General Practice, Zhaoxiang Community Health Centre Shanghai, China.
authors.forename: Huali
authors.initials: H
authors.lastname: Qin
authors.affiliation: Department of Pathology, Tongji Hospital, Tongji University School of Medicine Shanghai, China ; Department of Pathology, Labway Clinical Laboratory Shanghai Ltd. Shanghai, China.
authors.forename: Ziling
authors.initials: Z
authors.lastname: Huang
authors.affiliation: Department of Pathology, Tongji Hospital, Tongji University School of Medicine Shanghai, China.
authors.forename: Shuai
authors.initials: S
authors.lastname: Li
authors.affiliation: Department of Pathology, Tongji Hospital, Tongji University School of Medicine Shanghai, China.
authors.forename: Xuyou
authors.initials: X
authors.lastname: Zhu
authors.affiliation: Department of Pathology, Tongji Hospital, Tongji University School of Medicine Shanghai, China.
authors.forename: Jian
authors.initials: J
authors.lastname: He
authors.affiliation: Department of Microbiology, School of Basic Medical Sciences, Hubei University of Medicine Shiyan, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Yang
authors.affiliation: Department of Pathology, Tongji Hospital, Tongji University School of Medicine Shanghai, China.
authors.forename: Xiaoting
authors.initials: X
authors.lastname: Yu
authors.affiliation: Department of Pathology, Tongji Hospital, Tongji University School of Medicine Shanghai, China.
authors.forename: Xianghua
authors.initials: X
authors.lastname: Yi
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D060890:B7-H1 Antigen / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate
chemical_list: D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; C423236:CD274 protein, human
keywords: PD-L1; Serrated adenocarcinoma; immunotherapy; tumor prognosis